Related Experiment Video
Updated: Dec 14, 2025
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
The biological basis and function of GNAS mutation in pseudomyxoma peritonei: a review
Yu-Lin Lin1, Ru Ma1, Yan Li2
1Department of Peritoneal Cancer Surgery and Pathology, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian Street, Haidian District, Beijing, 100038, China.
Purpose:
Pseudomyxoma peritonei (PMP) is a rare clinical malignancy syndrome characterized by the uncontrollable accumulation of copious mucinous ascites in the peritoneal cavity, resulting in "jelly belly". The mechanism of tumor progression and mucin hypersecretion remains largely unknown, but GNAS mutation is a promising contributor. This review is to systemically summarize the biological background and variant features of GNAS, as well as the impacts of GNAS mutations on mucin expression, tumor cell proliferation, clinical-pathological characteristics, and prognosis of PMP.
Methods:
NCBI PubMed database (in English) and WAN FANG DATA (in Chinese) were used for literature search. And NCBI Gene and Protein databases, Ensembl Genome Browser, COSMIC, UniProt, and RCSB PDB database were used for gene and protein review.
Results:
GNAS encodes guanine nucleotide-binding protein α subunit (Gsα). The mutation sites of GNAS mutation in PMP are relatively stable, usually at Chr20: 57,484,420 (base pair: C-G) and Chr20: 57,484,421 (base pair: G-C). Typical GNAS mutation results in the reduction of GTP enzyme activity in Gsα, causing failure to hydrolyze GTP and release phosphoric acid, and eventually the continuous binding of GTP to Gsα. The activated Gsα could thus continuously promote mucin secretion through stimulating the cAMP-PKA signaling pathway, which is a possible mechanism leading to elevated mucin secretion in PMP.
Conclusion:
GNAS mutation is one of the most important molecular biological features in PMP, with major functions to promote mucin hypersecretion.
Insights
GNAS mutations are key drivers of pseudomyxoma peritonei (PMP), a rare cancer causing mucinous ascites. These mutations promote excessive mucin secretion, contributing to PMP progression and its characteristic "jelly belly" appearance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by extensive mucinous ascites.
- The underlying mechanisms of PMP progression and mucin overproduction are not fully understood.
- GNAS mutations are increasingly recognized as significant contributors to PMP pathogenesis.
Purpose of the Study:
- To systematically review the biological characteristics and variants of the GNAS gene.
- To elucidate the impact of GNAS mutations on mucin expression in PMP.
- To analyze the effects of GNAS mutations on tumor cell proliferation, clinical features, and patient prognosis in PMP.
Main Methods:
- Literature search conducted in the NCBI PubMed (English) and WAN FANG DATA (Chinese) databases.
- Comprehensive review of gene and protein information using NCBI Gene and Protein databases, Ensembl Genome Browser, COSMIC, UniProt, and RCSB PDB.
- Analysis of GNAS mutation sites and their functional consequences.
Main Results:
- GNAS encodes the guanine nucleotide-binding protein α subunit (Gsα).
- Specific GNAS mutation sites (Chr20: 57,484,420 and Chr20: 57,484,421) are frequently observed in PMP.
- Mutations impair Gsα's GTPase activity, leading to constitutive activation and continuous promotion of mucin secretion via the cAMP-PKA pathway.
Conclusions:
- GNAS mutation represents a critical molecular feature in PMP.
- These mutations are primarily responsible for the hallmark mucin hypersecretion observed in PMP.
- Targeting GNAS pathways may offer therapeutic strategies for PMP.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
